There are two problems associated with the systemic administration of EPO for the treatment of diseases in the nervous system: one problem is the poor transport of the protein across the blood-brain barrier (BBB) [7]; another problem is that the erythropoietic activity of EPO can cause polycythemia and thereby increase the risk of thrombosis or other adverse effects [9]. Here, EPO is linked to polycythemia.